Lista de obras - Nicolas Widmer - Dominio Público Uruguay

Benchmarking therapeutic drug monitoring software: a review of available computer tools

artículo científico

Biases affecting injected doses of an experimental drug during clinical trials.

artículo científico publicado en 2016

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.

artículo científico publicado en 2014

Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring

scientific article published on 30 June 2018

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

artículo científico publicado en 2010

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

artículo científico publicado en 2004

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

artículo científico publicado en 2010

Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs

artículo científico publicado en 2017

Emergency and Disaster Preparedness of European Hospital Pharmacists: A Survey

scientific article published on 19 November 2019

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature

artículo científico

Example-based support vector machine for drug concentration analysis

artículo científico publicado en 2011

Full-scale simulations to improve disaster preparedness in hospital pharmacies

artículo científico publicado en 2022

Functional consequence of MDR1 expression on imatinib intracellular concentrations

artículo científico publicado en 2003

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

article

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

artículo científico publicado en 2008

Imatinib plasma concentrations variability in oncologic patients

pharmacology book

Imatinib plasma levels: correlation with clinical benefit in GIST patients

artículo científico publicado en 2010

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

artículo científico publicado en 2014

Long-term prospective population PK study in GIST patients--letter

artículo científico publicado en 2013

Monitoring drug therapy.

artículo científico publicado en 2012

Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and

artículo científico publicado en 2010

Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

artículo científico publicado en 2005

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

artículo científico publicado en 2010

Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients

artículo científico publicado en 2020

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals

artículo científico publicado en 2014

Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates

artículo científico publicado en 2014

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

artículo científico publicado en 2006

Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours

artículo científico publicado en 2013

Prescription of Sedative Drugs During Hospital Stay: A Swiss Prospective Study.

artículo científico publicado en 2017

Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

artículo científico publicado en 2018

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

artículo científico publicado en 2008

Representation of Medical Guidelines with a Computer Interpretable Model

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels

artículo científico publicado en 2007

Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

artículo científico publicado en 2013

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics

artículo científico publicado en 2014

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies

artículo científico publicado en 2014

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

artículo científico publicado en 2005

Swiss Armed Forces deployment during the COVID-19 pandemic: militia pharmacy officers' roles and duties

scientific article published on 18 September 2020

Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes

artículo científico

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

artículo científico publicado en 2020

Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review

scientific article published on 01 February 2020

Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

scholarly article published 2012

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

artículo científico publicado en 2009

Therapeutic drug monitoring in cancer--are we missing a trick?

artículo científico publicado en 2014

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

artículo científico publicado en 2012

Therapeutic drug monitoring of targeted anticancer therapy

artículo científico

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

artículo científico publicado en 2014

Transition of care: A set of pharmaceutical interventions improves hospital discharge prescriptions from an internal medicine ward

artículo científico publicado en 2016

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.

artículo científico publicado en 2010

Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections

artículo científico publicado en 2020

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

artículo científico publicado en 2010

[Principles of therapeutic drug monitoring]

artículo científico publicado en 2008

[Therapeutic drug monitoring: clinical practice].

artículo científico publicado en 2008

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors

artículo científico publicado en 2010

Lista de obras de Nicolas Widmer

Benchmarking therapeutic drug monitoring software: a review of available computer tools

Biases affecting injected doses of an experimental drug during clinical trials.

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.

Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs

Emergency and Disaster Preparedness of European Hospital Pharmacists: A Survey

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature

Example-based support vector machine for drug concentration analysis

Full-scale simulations to improve disaster preparedness in hospital pharmacies

Functional consequence of MDR1 expression on imatinib intracellular concentrations

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

Imatinib plasma concentrations variability in oncologic patients

Imatinib plasma levels: correlation with clinical benefit in GIST patients

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

Long-term prospective population PK study in GIST patients--letter

Monitoring drug therapy.

Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and

Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals

Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours

Prescription of Sedative Drugs During Hospital Stay: A Swiss Prospective Study.

Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

Representation of Medical Guidelines with a Computer Interpretable Model

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels

Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

Swiss Armed Forces deployment during the COVID-19 pandemic: militia pharmacy officers' roles and duties

Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review

Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

Therapeutic drug monitoring in cancer--are we missing a trick?

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

Therapeutic drug monitoring of targeted anticancer therapy

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

Transition of care: A set of pharmaceutical interventions improves hospital discharge prescriptions from an internal medicine ward

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.

Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

[Principles of therapeutic drug monitoring]

[Therapeutic drug monitoring: clinical practice].

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors